Drug repurposing in the treatment of COVID-19: A review

The first outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was in Wuhan, Hubei, China in December 2019 and declared as a pandemic by the World Health Organization. Currently, there is no proven effective vaccine or therapeutic agent to combat the deadly coronavirus disease. Currently, prevention from the infection, control measures and supportive care help to treat against COVID-19. Until an effective vaccine is available for COVID-19 infection, one can repurpose known therapeutic agents that block the entry of the virus into the host cell and control the COVID-19 infection. Drug repurposing is the new use of old drugs. In this review, the most common and possible drug treatment for COVID-19 is highlighted. The therapeutic agents include antiviral drugs like Remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, umifenovir, favipiravir and oseltamivir and other agents. Clinical trials are ongoing to evaluate the safety and efficacy of these therapeutic agents in COVID-19 patients

Disproportionate rise in serum CA 125 in case of budd chiari syndrome: an unusual presentation

Ca 125 is used as a diagnostic and prognostic biomarker for ovarian cancer. The level of CA 125 is also elevated in benign conditions like Budd Chiari syndrome, liver cirrhosis and heart failure. But very high level of CA 125 is rarely associated with benign conditions and this can mislead the physician. Here we present a case of budd chiari syndrome in postpartum period associated with very high level of CA 125 which is an unusual presentation

A case report: primary CNS angiitis

The primary angiitis of the central nervous system (PACNS) is an entity with a very low incidence and prevalence. It affects small and medium sized arteries of the brain parenchyma, spinal cord and leptomeniges resulting in CNS dysfunction. It is defined by inflammation of the cerebral vasculature without angiitis of other organ. Its clinical manifestations are very heterogeneous and make clinical diagnosis difficult. In most cases, a brain biopsy is required. Only the clinical suspicion and the ability to recognize the possible clinical and imagenological patterns of presentation make an accurate diagnosis possible.We hereby report a case of Primary angiitis of CNS in 35 year old right handed male who presented with ischemic stroke with Left Hemiplegia. The diagnosis of PACNS was made after ruling out most of the causes of secondary CNS angiitis

Simultaneous spectrophotometric estimation of nitazoxanide and ofloxacin in tablets

Two simple, accurate and precise spectrophotometric methods have been developed for simultaneous determination of nitazoxanide and ofloxacin in tablets. Method I is Q-absorbance ratio method which involves Q-absorbance at isobestic point (306.25 nm) and max (347.5 nm) of nitazoxanide, while method II is two wavelength method, where 244.6 nm and 273.0 nm were selected as 1 and 2 for determination of nitazoxanide and 294.3 nm and 388.1 nm were selected as 3 and 4 for determination of ofloxacin. Both drugs obeyed the Beer′s law in the concentration range 2-30 μg/ml,correlation coefficient (r 2 <1). Both methods were validated statistically and recovery studies were carried out to confirm the accuracy. Commercial tablet formulation was successfully analyzed using the developed methods